1-3 of 3
Jack Shiansong Li
Close
Sort by
Journal Articles

Conditional Survival in Patients with Del(5q) Myelodysplastic Syndromes Treated with Lenalidomide

Aaron T. Gerds, MD MS, Alan F. List, MD, Aristoteles Giagounidis, MD PhD, Eva Hellström-Lindberg, MD PhD, Jack Shiansong Li, PhD, Arlene S. Swern, PhD, Mary M. Sugrue, MD PhD, Pierre Fenaux, MD PhD, Mikkael A. Sekeres, MD MS
Journal: Blood
Blood (2015) 126 (23): 2867.
https://doi.org/10.1182/blood.V126.23.2867.2867
Published: 2015
Journal Articles

p53 Mutant Independently Impacts Risk: Analysis of Deletion 5q, Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Lenalidomide (LEN) in the MDS-004 Study

Leonie Saft, MD PhD, Jack Shiansong Li, PhD, Peter L. Greenberg, MD PhD, Mikkael A. Sekeres, MD MS, Guillermo F. Sanz, MD PhD, François Dreyfus, MD, Pierre Fenaux, MD PhD, Arlene S. Swern, PhD, Mary M. Sugrue, MD PhD, Eva Hellstrom-Lindberg, MD PhD
Journal: Blood
Blood (2014) 124 (21): 414.
https://doi.org/10.1182/blood.V124.21.414.414
Published: 2014
Journal Articles

Association Of Cytogenetic Response (CyR) With RBC Transfusion-Independence (RBC-TI) and AML-Free Survival In Lenalidomide (LEN)-Treated Patients (Pts) With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) With Del(5q)

Mikkael A. Sekeres, MD, MS, Arlene S. Swern, PhD, Aristoteles Giagounidis, MD, PhD, Alan List, MD, Brigitte Schlegelberger, MD, PhD, Pierre Fenaux, MD, PhD, Jack Shiansong Li, Mary M. Sugrue, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 390.
https://doi.org/10.1182/blood.V122.21.390.390
Published: 2013